Clinical Trials
116
Active:7
Completed:65
Trial Phases
4 Phases
Phase 1:34
Phase 2:21
Phase 3:53
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (109 trials with phase data)• Click on a phase to view related trials
Phase 3
53 (48.6%)Phase 1
34 (31.2%)Phase 2
21 (19.3%)Phase 4
1 (0.9%)A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 50
- Registration Number
- NCT07020988
- Locations
- 🇺🇸
Up0127 1001, Glendale, California, United States
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 32
- Registration Number
- NCT06970301
- Locations
- 🇺🇸
Up0135 1001, Glendale, California, United States
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 15
- Registration Number
- NCT06961747
- Locations
- 🇺🇸
UP0137 2, San Antonio, Texas, United States
🇺🇸UP0137 1, Salt Lake City, Utah, United States
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 40
- Registration Number
- NCT06921850
- Locations
- 🇺🇸
Hs0006 50708, Roseville, California, United States
🇺🇸Hs0006 50178, Clarkston, Michigan, United States
🇺🇸Hs0006 50710, Fort Gratiot, Michigan, United States
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Phase 1
Recruiting
- Conditions
- Moderate to Severe Plaque PsoriasisPsoriatic ArthritisAxial SpondyloarthritisHidradenitis Suppurativa
- Interventions
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 20
- Registration Number
- NCT06888193
- Locations
- 🇨🇦
Up0122 202, Calgary, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 24
- Next
News
No news found